Compare Lululemon Athletica Inc (LULU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs Recursion Pharmaceuticals Inc — how do they compare? Lululemon Athletica Inc trades at $113.65 (market cap $13.24B), while Recursion Pharmaceuticals Inc trades at $3.01 (market cap $1.63B). The key difference: Lululemon Athletica Inc is far larger — about 8.1× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| LULU | RXRX | |
|---|---|---|
Market Cap | $13.24B | $1.63B |
Sector | Consumer Cyclical | Health |
52-Week High | $224.03 | $6.79 |
52-Week Low | $105.43 | $2.84 |
Enterprise Value | $13.87B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon trades at $116.63, up 0.26% today, amid bearish technical signals but strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.69 exceeding the $1.67 estimate. Revenue grew to $10.59B in 2025, with a net income margin of 17.13%. Recent news includes a $30M investment in nylon recycling startup Syntetica and resolution of a proxy battle with founder Chip Wilson, boosting shareholder confidence.
The outlook is mixed: valuation metrics like a P/E of 9.45 and EV/EBITDA of 5.41 suggest potential upside to the $129.29 consensus target, but technical bearishness and competitive pressures pose risks. Investors may find value in robust profitability and strategic initiatives, though macroeconomic headwinds and brand controversies require monitoring.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
